Last 868.40 INR
Change Today +21.05 / 2.48%
Volume 148.4K
EMER On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

merck ltd (EMER) Snapshot

Open
848.00
Previous Close
847.35
Day High
894.00
Day Low
845.00
52 Week High
09/22/14 - 894.00
52 Week Low
02/3/14 - 535.00
Market Cap
14.4B
Average Volume 10 Days
61.4K
EPS TTM
33.70
Shares Outstanding
16.6M
EX-Date
03/10/14
P/E TM
25.8x
Dividend
8.50
Dividend Yield
0.98%
Current Stock Chart for MERCK LTD (EMER)

Related News

No related news articles were found.

merck ltd (EMER) Related Businessweek News

No Related Businessweek News Found

merck ltd (EMER) Details

Merck Limited manufactures and markets pharmaceuticals, bulk drugs, fine chemicals, and pigments primarily in India. The company operates in two segments, Pharmaceuticals and Chemicals. The Pharmaceuticals segment offers multi-vitamin products, such as Evion, Neurobion, and Polybion; Concor for cardio-vascular care; Carbophage for metabolic disorders; Livogen for haematinics treatment; and immuno-stimulator products comprising Immubron and Pedimune. This segment also provides consumer health care products, such as cough and cold, health protection, and women and children health products under the Nasivion, SevenSeas Original, Maxepa, Electrobion, and Evion Cream. The Chemicals segment primarily provides active pharmaceutical ingredients, excipients, and bio-pharmaceuticals for pharma and biopharma industries; pigments for the automotive, cosmetics, plastics, printing, and security industries; and various actives for the cosmetics industry, as well as functional and pearl luster effect pigments. Merck Limited also exports its products to Asian and African countries, such as Sri Lanka, Nepal, Lebanon, Kenya, Libya, and others. The company, formerly known as E. Merck Limited, was founded in 1967 and is based in Mumbai, India. Merck Limited is a subsidiary of Merck KGaA.

1,496 Employees
Last Reported Date: 02/24/14
Founded in 1967

merck ltd (EMER) Top Compensated Officers

Managing Director, Additional Director and Me...
Total Annual Compensation: 17.9M
Chief Financial Officer, Director of Finance,...
Total Annual Compensation: 6.6M
Vice President of Technical Operations, Whole...
Total Annual Compensation: 9.7M
Compensation as of Fiscal Year 2013.

merck ltd (EMER) Key Developments

Merck Ltd. Reports Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Merck Ltd. reported unaudited standalone earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of INR 2,326.480 million, profit from operations before other income finance costs and exceptional items of INR 316.318 million, profit from ordinary activities before tax of INR 316.318 million and net profit of INR 209.983 million or INR 12.65 per basic and diluted share after extraordinary items (not annualised) compared to net sales of INR 2,002.938 million, profit from operations before other income finance costs and exceptional items of INR 255.065 million, profit from ordinary activities before tax of INR 255.065 million and net profit of INR 166.632 million or INR 10.05 per basic and diluted share after extraordinary items (not annualised) reported in the same period last year. For the six months, the company reported net sales of INR 4,198.000 million, profit from operations before other income finance costs and exceptional items of INR 376.518 million, profit from ordinary activities before tax of INR 376.518 million and net profit of INR 245.551 million or INR 14.79 per basic and diluted share after extraordinary items (not annualised) compared to net sales of INR 3,769.425 million, profit from operations before other income finance costs and exceptional items of INR 480.953 million, profit from ordinary activities before tax of INR 460.953 million and net profit of INR 306.594 million or INR 18.47 per basic and diluted share after extraordinary items (not annualised) reported in the same period last year.

Merck Ltd., Board Meeting, Aug 12, 2014

Merck Ltd., Board Meeting, Aug 12, 2014. Agenda: To consider unaudited standalone earnings results for the second quarter and six months ended June 30, 2014.

Merck Ltd., Board Meeting, Apr 30, 2014

Merck Ltd., Board Meeting, Apr 30, 2014. Agenda: To approve quarterly results.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EMER:IN 868.40 INR +21.05

EMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $105.96 USD +0.03
Koninklijke DSM NV €50.10 EUR -0.18
Lonza Group AG SFr.118.00 CHF +1.60
Sigma-Aldrich Corp $102.37 USD -0.93
Thermo Fisher Scientific Inc $123.24 USD -0.89
View Industry Companies
 

Industry Analysis

EMER

Industry Average

Valuation EMER Industry Range
Price/Earnings 27.9x
Price/Sales 1.7x
Price/Book 2.5x
Price/Cash Flow 22.6x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK LTD, please visit www.merck.co.in. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.